| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CCD.10497 |
| P698 | PubMed publication ID | 12822144 |
| P2093 | author name string | Ulrich Walter | |
| Antoine Lafont | |||
| Martin Eigenthaler | |||
| Laurence Camoin | |||
| Paul Barragan | |||
| Philippe Commeau | |||
| Jean-Louis Bouvier | |||
| Bertrand Comet | |||
| Gilles Macaluso | |||
| Pierre-Olivier Roquebert | |||
| P2860 | cites work | Rapid platelet-function assay: an automated and quantitative cartridge-based method | Q39486128 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorylation | Q242736 |
| thrombosis | Q261327 | ||
| P304 | page(s) | 295-302 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Catheterization and Cardiovascular Interventions | Q2352240 |
| P1476 | title | Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation | |
| P478 | volume | 59 |
| Q46624023 | "Short" thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility |
| Q36131394 | A comparison of two brands of clopidogrel in patients with drug-eluting stent implantation |
| Q46244126 | A paradigm shift in anti-platelet therapy? |
| Q40329955 | A point-of-care assay to measure platelet aggregation in patients taking clopidogrel |
| Q35764145 | A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI |
| Q36715768 | AZD6140. |
| Q37668119 | Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes |
| Q38037121 | Advances in the monitoring of anti-P2Y12 therapy. |
| Q38958862 | Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors |
| Q40014803 | Antiplatelet Resistance-Does it Exist and How to Measure it? |
| Q37437158 | Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements |
| Q28201011 | Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4 |
| Q37882712 | Antiplatelet drug therapy: role of pharmacodynamic and genetic testing |
| Q42930834 | Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest |
| Q37914924 | Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents |
| Q28199136 | Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter? |
| Q37838100 | Antiplatelet therapy and vascular disease: an update. |
| Q36941850 | Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives |
| Q40329892 | Antiplatelet therapy: current strategies and future trends |
| Q38715643 | Antithrombotic therapy in peripheral artery disease |
| Q47150639 | Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans |
| Q28200610 | Aspirin and clopidogrel resistance: consideration and management |
| Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
| Q37164379 | Assessing the current role of platelet function testing. |
| Q57072916 | Association of rs2254638 Polymorphism With Clopidogrel Response in Chinese Patients With Coronary Artery Disease |
| Q47141908 | Baseline platelet parameters for predicting early platelet response and clinical outcomes in patients with non-cardioembolic ischemic stroke treated with clopidogrel |
| Q37707419 | Benefits of and safety concerns associated with drug-eluting coronary stents |
| Q33639452 | Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome |
| Q38059616 | Clinical impact of genetically determined platelet reactivity |
| Q34390050 | Clinical importance of aspirin and clopidogrel resistance |
| Q37841560 | Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention |
| Q38154064 | Clopidogrel "resistance": pre- vs post-receptor determinants. |
| Q34212563 | Clopidogrel "resistance": where are we now? |
| Q45060966 | Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding |
| Q50676873 | Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100). |
| Q37786639 | Clopidogrel in acute coronary syndrome: implications of recent study findings |
| Q37627874 | Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations |
| Q51906913 | Clopidogrel poor responders: an objective definition based on Bayesian classification. |
| Q42003164 | Clopidogrel resistance "Live" - the risk of stent thrombosis should be evaluated before procedures |
| Q36649824 | Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents |
| Q36819608 | Clopidogrel resistance--the cardiologist's perspective |
| Q40347840 | Clopidogrel resistance: fact and fiction |
| Q28218055 | Clopidogrel resistance: myth or reality? |
| Q38128171 | Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes |
| Q30573045 | Clopidogrel: the data, the experience, and the controversies |
| Q53005242 | Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. |
| Q38065124 | Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. |
| Q42850846 | Comparison of Platelet P2Y12 ADP Receptor-Mediated Pathway Inhibition in Triple Versus Dual Antiplatelet Therapy as Assessed by VASP-Phosphorylation in Japanese Patients Undergoing Coronary Stenting |
| Q37629641 | Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. |
| Q33765033 | Cordycepin-Enriched WIB801C from Cordyceps militaris Inhibits Collagen-Induced [Ca(2+)]i Mobilization via cAMP-Dependent Phosphorylation of Inositol 1, 4, 5-Trisphosphate Receptor in Human Platelets |
| Q53271322 | Cordycepin-enriched WIB801C from Cordyceps militaris inhibits ADP-induced [Ca(2+)] i mobilization and fibrinogen binding via phosphorylation of IP 3R and VASP. |
| Q37582058 | Coronary stent thrombosis in patients with chronic renal insufficiency. |
| Q26771106 | Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications |
| Q54236665 | Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. |
| Q42871091 | Determination of the Prevalence of Aspirin and Clopidogrel Resistances in Patients with Coronary Artery Disease by using Various Platelet-function Tests |
| Q37752222 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. |
| Q28221675 | Double-trouble: three cases with simultaneous stent thrombosis in different coronary arteries |
| Q28198683 | Drug insight: Clopidogrel nonresponsiveness |
| Q37697780 | Drug interaction between clopidogrel and proton pump inhibitors |
| Q34983154 | Drug-drug interaction between clopidogrel and the proton pump inhibitors. |
| Q34865151 | Effect of Cordycepin-Enriched WIB801C from Cordyceps militaris Suppressing Fibrinogen Binding to Glycoprotein IIb/IIIa |
| Q46638114 | Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. |
| Q54546944 | Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance. |
| Q37016139 | FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations |
| Q45213002 | Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases |
| Q38396605 | Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis |
| Q51905748 | Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q28194081 | High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome |
| Q46929670 | High postclopidogrel platelet reactivity in non-ST-elevation acute coronary syndrome treated with stenting: a clue for adverse prognosis? |
| Q26824850 | High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance |
| Q47210349 | Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients |
| Q34536091 | Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism |
| Q36082585 | Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation |
| Q38154612 | Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account |
| Q35985453 | Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials |
| Q38012079 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q28193674 | Medications for the treatment of acute coronary syndromes |
| Q51572866 | Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. |
| Q38099235 | Monitoring aspirin and clopidogrel response: testing controversies and recommendations |
| Q37562606 | P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. |
| Q38542096 | P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use |
| Q37339517 | P2Y12 inhibitors in cardiovascular disease: focus on prasugrel |
| Q26745619 | P2Y12-ADP receptor antagonists: Days of future and past |
| Q37642822 | Personalized antiplatelet therapy for coronary artery disease patients: is this the future? |
| Q26775125 | Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls |
| Q37877165 | Personalized antiplatelet therapy: review of the latest clinical evidence |
| Q42164176 | Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial |
| Q38154211 | Pharmacology of antiplatelet agents |
| Q37678656 | Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions |
| Q34035039 | Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS? |
| Q46358660 | Platelet function profile post-clopidogrel therapy in patients with type 2 diabetes undergoing coronary stent implantation |
| Q38080466 | Platelet function testing in patients with acute coronary syndrome |
| Q38089082 | Platelet function tests for the monitoring of P2Y12 inhibitors |
| Q43077737 | Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy |
| Q41349792 | Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place |
| Q37693085 | Poor response to clopidogrel: current and future options for its management |
| Q28210429 | Prasugrel |
| Q28196661 | Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease |
| Q46761762 | Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation |
| Q39908656 | Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system |
| Q37540088 | Recent developments in clopidogrel pharmacology and their relation to clinical outcomes |
| Q43126759 | Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. |
| Q43405386 | Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay |
| Q57764181 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel a |
| Q28192298 | Resistance to antiplatelet drugs: current status and future research |
| Q37807524 | Resistance to aspirin and clopidogrel therapy. |
| Q46656412 | Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases |
| Q37799470 | Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians |
| Q37809630 | Review: Antiplatelet drugs: what comes next? |
| Q40010554 | Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease |
| Q41962888 | Stent thrombosis: incidence, predictors and new technologies |
| Q64239259 | The MOVEMENT Trial |
| Q37923969 | The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders |
| Q53298721 | The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12receptor inhibition |
| Q37204401 | The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice |
| Q45710707 | Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. |
| Q37552005 | Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist |
| Q36437891 | Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP (Ser(157)) and dephosphorylation of PI3K and Akt |
| Q37479082 | Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention |
| Q50940673 | Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population. |
| Q46888764 | Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes |
| Q55517618 | Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats. |
| Q53554561 | Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. |
| Q37314349 | Vasodilator-stimulated phosphoprotein-phosphorylation by ginsenoside Ro inhibits fibrinogen binding to αIIb/β3 in thrombin-induced human platelets |
Search more.